Parkinson's disease
Conditions
Interventions
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
55 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. All PD patients fulfilled the diagnostic criteria of MDS in 2015; 2. Patients with primary Parkinson's disease aged 55 -75; 3. Hoehn and Yahr stages 1-2.5 were enrolled in this study; 4. Informed consent was obtained from all participants; 5. MMSE >= 24
Exclusion criteria
Exclusion criteria: 1. Parkinson's syndrome and Parkinson's syndrome are caused by drugs, poisoning, metabolic diseases, intracranial infection, genetics, trauma, tumor, autoimmune diseases, cerebrovascular diseases, and other reasons; 2. Patients' compliance is affected due to cognitive dysfunction and informed consent cannot be signed. (Note: In suspicious cases, informed consent should be provided only when a physician not involved in the study confirms that the patient is not dementia, excluding patients with MMSE <= 24). 3. Patients with a history of mental illness; 4. Had a history of active epilepsy (i.e., seizures) within two years prior to enrollment; Patients with degree II or III ATrioventricular block or pathological sinus syndrome; 6. The patient's resting heart rate is lower than 50 beats/min; Patients with congestive heart failure are classified as class III or IV according to the New York Heart Association cardiac function classification; 8. Patients with myocardial infarction within 6 months before enrollment. 9. Other heart diseases (e.g., coronary artery disease) that are clinically significant and may interfere with the completion of the trial; 10. Clinically significant kidney disease that may prevent the patient from completing the test, and/or serum creatinine above the laboratory normal range, and/or blood urea nitrogen above 1.5 times the normal range; 11. Clinically significant liver disease, which may prevent patients from completing the test, and/or total bilirubin, glutamic-oxalacetic transaminase, or glutamic-pyruvic transaminase higher than the normal value in the laboratory, that is, more than 1.2 times the normal value, but still higher than the normal value after review. 12. Patients who are suffering from cancer, or have a history of cancer or a family history of cancer; 13. Patients had a history of surgical procedures in the 180 days prior to enrollment, which the investigator suggested might influence participants in the clinical trial and patients with a history of stereotactic brain surgery; 14. Systolic blood pressure decreased by 20mmHg 5 minutes after being upright compared to the previous measurement of systolic blood pressure after 5 minutes of quiet rest in a recumbent position, and blood pressure decreased with symptoms (i.e., symptomatic postural hypotension); 15. Women of childbearing age who are not taking oral contraceptives/using medically approved contraceptives (Note: all women of childbearing age are required to have a pregnancy test before inclusion); 16. The patient is participating in another clinical trial or was enrolled in another study within the 90 days prior to enrollment. In addition, patients who were randomly enrolled in the study and then dropped out may not be re-enrolled; 17. Skin of the scalp and information collection area has ulceration; 18. Metal implants that affect MRI examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UPDRS(United Parkinson’s Disease Rating Scale); | — |
Secondary
| Measure | Time frame |
|---|---|
| NFL-Neurofilament light;a-synuclein;Amyloid-ß 40, Amyloid-ß 42;electroencephalograph;Head magnetic resonance imaging;MMSE-Mini-mental State Examination;MoCA-Montreal Cognitive Assessment Test;PDSS-2( Parkinson's disease sleep scale-2);NMSS(non-motor symptoms scale);HAMD(Hamilton Depression Rating Scale);microtubule-associated protein tau; | — |
Countries
China
Contacts
Public ContactXiaodong Zhu
Outcome results
None listed